Is Inventiva S.A. (IVA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 4.3% / 30% | 7.6% / 30% | 1.0% / 30% | 12.43% / 5% | ✗ NOT HALAL |
| DJIM | 4.3% / 33% | 7.6% / 33% | 1.0% / 33% | 12.43% / 5% | ✗ NOT HALAL |
| MSCI | 45.7% / 33% | 81.2% / 33% | 10.2% / 33% | 12.43% / 5% | ✗ NOT HALAL |
| S&P | 4.3% / 33% | 7.6% / 33% | 1.0% / 33% | 12.43% / 5% | ✗ NOT HALAL |
| FTSE | 45.7% / 33% | 81.2% / 33% | 10.2% / 50% | 12.43% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 95.2% | |
| Operating Margin | -991.9% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -56.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$86M |
| Free Cash Flow | -$86M |
| Total Debt | $54M |
| Current Ratio | 3.0 |
| Total Assets | $119M |
Price & Trading
| Last Close | $6.09 |
| 50-Day MA | $6.30 |
| 200-Day MA | $4.90 |
| Avg Volume | 438K |
| Beta | 0.9 |
|
52-Week Range
$2.85
| |
About Inventiva S.A. (IVA)
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Inventiva S.A. (IVA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Inventiva S.A. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Inventiva S.A.'s debt ratio?
Inventiva S.A.'s debt ratio is 4.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 45.7%.
What are Inventiva S.A.'s key financial metrics?
Inventiva S.A. has a market capitalization of $1.2B, and revenue of $9M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.